Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CS DiagnosticsCSDX EBITDA Margin % is -41.49% as of Dec. 2025. The stock has 1 warning sign investors should review. Among 815 Medical Devices & Instruments companies, CS Diagnostics ranks worse than 79.26% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. CS Diagnostics's EBITDA for the
three
months ended in Dec. 2025 was $0.04 Mil. CS Diagnostics's Revenue for the
three
months ended in Dec. 2025 was $-0.09 Mil. Therefore, CS Diagnostics's EBITDA margin for the quarter that ended in Dec. 2025 was -41.49%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
CS Diagnostics EBITDA Margin % Related Terms
CS Diagnostics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for CS Diagnostics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSDX vs NMTC, IRIX, LFWD: EBITDA Margin % Comparison
For the Medical Devices subindustry, CS Diagnostics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CS Diagnostics EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CS Diagnostics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where CS Diagnostics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CS Diagnostics (CSDX) has a EBITDA Margin % of -41.49% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CS Diagnostics and its competitors. According to the industry distribution chart, CS Diagnostics ranks #646 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 79.3%.
Is CS Diagnostics' EBITDA Margin % too high?
CS Diagnostics' current EBITDA Margin % is -41.49%. Based on the distribution chart, CS Diagnostics ranks #646 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does CS Diagnostics' EBITDA Margin % compare to NMTC and IRIX?
According to the Medical Devices & Instruments industry distribution chart, CS Diagnostics ranks #646 out of 815 companies for EBITDA Margin %. This places CS Diagnostics in the lower half of its industry. The industry median EBITDA Margin % is 7.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CS Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CS Diagnostics's current EBITDA Margin % is -41.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CS Diagnostics stock overvalued right now?
CS Diagnostics (CSDX) has a current EBITDA Margin % of -41.49%. The current EBITDA Margin % is -41.49%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CS Diagnostics (CSDX), the current EBITDA Margin % is -41.49% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CS Diagnostics Corp is a United States based Corporation, its focus is on improving therapy results and reducing side effects. In addition, it offers international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, it develops its own products with the aim of maximizing patient benefit.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSDX has been successfully added to your 
